Advaxis, Inc.  

(Public, NASDAQ:ADXS)   Watch this stock  
Find more results for OTC:ADXS
+0.06 (0.71%)
Real-time:   2:30PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.70 - 7.97
52 week 5.21 - 22.20
Open 7.83
Vol / Avg. 275,320.00/644,331.00
Mkt cap 270.86M
P/E     -
Div/yield     -
EPS -1.86
Shares 34.35M
Beta 1.55
Inst. own 61%
Jul 13, 2016
Advaxis Inc at Cantor Fitzgerald Healthcare Conference
Jun 28, 2016
Advaxis Inc Investor and Analyst Day - Webcast
Jun 9, 2016
Advaxis Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Apr '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -57.37% -65.79%
Return on average equity -62.14% -69.05%
Employees 48 -
CDP Score - -


305 College Rd E
PRINCETON, NJ 08540-6608
United States - Map
+1-732-5451590 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Advaxis, Inc. is a clinical-stage biotechnology company. The Company's immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies. The Company's immunotherapy candidates include Axalimogene filolisbac, ADXS-PSA and ADXS-HER2. Axalimogene filolisbac (ADXS-HPV) is a lead Lm-LLO immunotherapy product candidate for the treatment of human papilloma virus (HPV) associated cancers. ADXS-PSA is an Lm-LLO immunotherapy product candidate designed to target the Prostate Specific Antigen (PSA) associated with prostate cancer. ADXS-HER2 is an Lm-LLO immunotherapy product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric and other cancers.

Officers and directors

Daniel J. O'Connor Esq. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Sara M. Bonstein Chief Financial Officer, Senior Vice President
Age: 35
Bio & Compensation  - Reuters
Gregory T. Mayes III Chief Operating Officer, Executive Vice President, Secretary, IR Contact Officer
Age: 47
Bio & Compensation  - Reuters
Robert G. Petit Ph.D. Executive Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
David Sidransky M.D. Non-Executive Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
James P. Patton M.D. Non-Executive Independent Vice Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Roni A. Appel Independent Director
Age: 49
Bio & Compensation  - Reuters
Richard J. Berman J.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Samir N. Khleif Independent Director
Age: 52
Bio & Compensation  - Reuters